L'hospitalet De Llobregat

• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended recruitment
  2024-517818-15-00 9 2025-06-06 Non-Small Cell Lung Cancer
• A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti­IL­33 mAb) in participants with inadequately-controlled … Ended recruitment
  2024-516815-26-00 5 2025-05-30 Chronic rhinosinusitis with nasal polyps
• A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced … Ended recruitment
  2024-512504-19-00 1 2025-05-28 solid tumors
• Dose escalation/expansion trial with BYON4228 alone and in combination in metastatic solid tumors Ended recruitment
  2024-517952-37-00 9 2025-05-22 Locally advanced or metastatic cancer (Solid tumors)
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors. Ended recruitment
  2024-516733-12-00 1 2025-05-13 Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorect
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration- … Ended recruitment
  2024-513968-25-00 5 2025-04-28 Metastatic castration-resistant prostate cancer (mCRPC)
• A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01) Ended recruitment
  2024-517741-14-00 9 2025-04-22 advanced non-squamous non-small cell lung cancer (NSCLC)
• A clinical study of pembrolizumab and other treatments for non-small cell lung cancer (MK-3475-01G) Ended recruitment
  2024-515772-12-00 4 2025-04-18 Lung neoplasm malignant (Stage IV Non-small cell lung cancer)
• A research study comparing how well different doses of the medicine NNC0519-0130 can reduce kidney damage in people living with chronic kidn … Ended recruitment
  2024-510846-15-00 4 2025-04-14 Chronic Kidney Disease, with or without Type 2 diabetes, Obesity
• A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec … Ended recruitment
  2023-507306-13-00 4 2025-04-13 HER2-positive unresectable locally recurrent or metastatic breast canc
• Study to evaluate the safety and efficacy of a treatment consisting of immunotherapy by subcutaneous injection of a combination of Der p 1/D … Ended recruitment
  2024-518519-20-01 4 2025-04-10 moderate/severe allergic rhinitis/rhinoconjunctivitis with/without con
• A Proof of Concept study to assess the efficacy, safety and tolerability of itepekimab (anti­IL­33 mAb) in participants with chronic rhinosi … Ended recruitment
  2024-515576-12-00 4 2025-03-20 Respiratory tract diseases
• CHAPTER-3 – A randomised clinical trial to assess efficacy and safety of deucrictibant treatment in prophylaxis against HAE attacks in adult … Ended recruitment
  2024-516247-62-00 5 2025-03-10 Hereditary Angioedema
• Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon®) in Pancreatic Exocrine Insufficiency (PEI) due to gastrectomy. Ended recruitment
  2023-507837-18-00 6 2025-03-06 Male and female patients aged ≥ 18 to ≤ 80 after total gastrectomy.
• A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration … Ended recruitment
  2024-515022-88-00 5 2025-03-03 Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA
• BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long- Term Safety and Efficacy of Tegoprubart in Kidney … Ended recruitment
  2023-503337-21-00 4 2025-02-28 Prophylaxis of Renal Allograft Rejection
• A Phase 3 Study of Brepocitinib in Adults with Active, Non-Infectious, Non-Anterior Uveitis (CLARITY) Ended recruitment
  2024-515089-15-00 5 2025-02-28 active non-infectious uveitis (intermediate uveitis, posterior uveitis
• Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended recruitment
  2024-515538-34-00 10 2025-02-27 Head and Neck Squamous Cell Carcinoma
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended recruitment
  2024-518343-38-00 5 2025-02-12 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn … Ended recruitment
  2023-505394-32-00 5 2025-02-06 chronic graft versus host disease
• A clinical trial to learn about the effects of YTB323 in people with difficult-to-treat severe inflammatory myopathies (IIM) Ended recruitment
  2024-514137-38-00 4 2025-02-04 Severe refractory idiopathic inflammatory myopathies (IIM)
• A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab … Ended recruitment
  2024-511650-50-00 5 2025-01-17 METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Showing 481–504 of 1,017 trials